Literature DB >> 3622947

The safety profile of De-Nol.

J P Bader.   

Abstract

The safety profile of colloidal bismuth subcitrate (CBS, De-Nol) is reviewed in the light of the situation surrounding bismuth-containing preparations in general. The unique outbreak of bismuth intoxication which occurred in France in the previous decade is examined and an attempt is made to explain it. The conclusion is drawn that the misuse of bismuth salts, which were taken in very large quantities and for prolonged periods, was very likely the responsible factor. Unlike the preparations involved with neurotoxicity in France, CBS complies in every respect to the present requirements for a modern drug. CBS is a potent peptic ulcer-healing agent acting at the level of mucosal defense. Side effects so far reported both in clinical trials and from practising physicians have been very infrequent, mild and transient.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3622947     DOI: 10.1159/000199559

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  10 in total

1.  The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy.

Authors:  Francis Mégraud
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.409

2.  [Pharmacokinetics of bismuth preparations in patients with gastritis and ulcer disease].

Authors:  R Raedsch; I Walter-Sack; E Weber; J Blessing
Journal:  Klin Wochenschr       Date:  1990-05-04

3.  Neuropsychiatric symptoms following bismuth intoxication.

Authors:  G T Eskens
Journal:  Postgrad Med J       Date:  1988-09       Impact factor: 2.401

4.  Binding of bismuth to cell components: clue to mode of action and side effects.

Authors:  M Locke; H Nichol; C Ketola-Pirie
Journal:  CMAJ       Date:  1987-12-01       Impact factor: 8.262

5.  Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori.

Authors:  T Rokkas; C Pursey; E Uzoechina; L Dorrington; N A Simmons; M I Filipe; G E Sladen
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

Review 6.  Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A J Wagstaff; P Benfield; J P Monk
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 7.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 8.  Renal effects of peptic ulcer therapy.

Authors:  E Burgess; D Muruve
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 9.  Pharmacokinetics and toxicity of bismuth compounds.

Authors:  A Slikkerveer; F A de Wolff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct

Review 10.  Treatment of peptic ulcer disease in the arthritic patient.

Authors:  D Nunes; N P Kennedy; D G Weir
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.